Cost-Effectiveness of Improved Primary Care Treatment of Depression in Women in Chile

This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness of alternate sequences of treatment strategies using second-generation antipsychotics (SGAs) for patients with schizophrenia. First-line treatments include one of the four SGAs: olanzapine (OLZ), risperidone (RSP), quetiapine (QTP), and ziprasidone (ZSD). Patients are able switch to another of these antipsychotics as second-line therapy, and only clozapine (CLZ) is allowed as third-line treatment. Model input parameters were obtained from the Clinical…

This article, published in Acta Psychiatrica Scandinavica, describes a Markov model that estimates the cost-effectiveness of aripiprazole versus olanzapine in the treatment of patients with schizophrenia or bipolar disorder in Sweden with a focus on the metabolic impact of the treatments. The health-state transition model consists of five health states: no metabolic syndrome, metabolic syndrome, diabetes, coronary heart disease, and death. The analyses are conducted over a lifetime, with a cycle length of one year.…

This article, published in Value in Health, describes the development of a Markov model to compare the cost-effectiveness of repetitive transcranial magnetic stimulation (rTMS) therapy with pharmacotherapy for the treatment of patients with treatment-resistant major depressive disorder. Pharmacotherapy includes selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclics, noradrenergic and specific serotonergic antidepressants, and monoamine oxidase inhibitors. Data on model input parameters are obtained from published literature, national cost reports, and expert opinions. Analyses…